HOME >> Investor Relations >>Top Message >> Message Archive (January 5, 2017)

PRINT

To Our Investors

Happy New Year! The coming year is going to be an important one for Japan Tissue Engineering (J-TEC), as we plan to move into the black for the first time in our corporate history. I sincerely hope that we will continue to have your support in 2017.

What we accomplished during the past half year

Time flew, and it has already been six months since I became the president here at J-TEC. During this time, with the support of all employees, the company made considerable achievements, as well as changes in various aspects.

In December 2016, just as we projected, J-TEC’s autologous cultured epidermis, JACE, was listed as an item covered by the National Health Insurance for the additional indication for “Giant Congenital Melanocytic Nevus (GCMN)” treatment. Our sales force has been activated, already taking orders from medical institutions. J-TEC will provide a new treatment option for patients with GCMN, and at the same time, this additional indication will become an important engine for our growth in the 4th quarter.

Under the new management, we hold executive meetings more often to discuss business operations and collaborate closely to enhance the enforcement power towards profitability.
We are now incorporating Fujifilm’s method of placing great importance to the management through figures, and taking initiative in business. In order to clearly show our future goals to the investors and shareholders, I have vastly renewed the contents of the briefing materials for financial statements since the 2nd quarter.

It is my strong belief that the growth of each employee is the driving force behind that of the company. Recently, the young generations here at J-TEC have launched a study group on regenerative medicine. Overcoming work boundaries, they themselves take the lead to create a platform to learn together and discuss about the future of regenerative medicine. “Have courage, and carry out your word” is the slogan I have set for the second half of this year, and I am feeling a good response.


study meeting on regenerative medicine

study meeting on regenerative medicine

Outlook for 2017

“J-TEC will outgrow from a bio venture to be a true leading company in the field of regenerative medicine.” I have personally delivered this message to the directors and employees at J-TEC right after I assumed the presidency. While maintaining the bio venture spirit of brave challenge, we must develop a strong management and financial bedrock and continuously grow and generate profit. The new FY2017 will be the year for us to make the first step towards it. We continue to expand the JACE and JACC business, together with the new business development and expansion as a Contract Development and Manufacturing Organization (CDMO). The CDMO business utilizes our expertise accumulated through JACE and JACC, and it will contribute greatly not only to the company’s growth, but also to the industrialization of regenerative medicine in Japan. Please look forward to our next leap ahead in the FY2017.

January 5, 2017
Aiichiro Hiruma
President & CEO
Japan Tissue Engineering Co., Ltd.